Breast Cancer Biomarkers and Clinical Translation
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".
Deadline for manuscript submissions: 31 May 2024 | Viewed by 2039
Special Issue Editors
2. Department of Oncology, Pisa University Hospital, 56126 Pisa, Italy
Interests: pathology; tumour microenvironment; molecular genetics; breast cancer
Special Issues, Collections and Topics in MDPI journals
Interests: breast cancer; resistance; targeted therapy; biomarkers
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Breast cancer represents the second most common cancer in women, its high mortality rate causing millions of cancer-related deaths annually. Thus, discovering and optimizing biomarkers that can improve breast cancer diagnosis, prognosis and therapeutic outcomes are needed. Diagnostic biomarkers are required for accurate diagnosis or to improve breast cancer risk prediction, including factors that integrate radiologic imaging and molecular pathology. Prognostic biomarkers provide information regarding the risk of recurrence and survival. Predictive biomarkers are tools for selecting patients who may benefit from specific therapy regimens. Translational research builds the bridge between discovering biomarkers in preclinical studies and testing their application in the clinical setting.
This Special Issue on “Breast Cancer Biomarkers and Clinical Translation” will provide a portrait of the current knowledge on novel biomarkers at the genomic, transcriptomic, proteomic, and immunologic levels and therapeutic strategies, together with advanced experimental approaches, in the management of breast cancer patients, thanks to a collection of high-level manuscripts in this field of research. Authors are welcome to submit original research articles, short communications of preliminary, but significant, experimental results and review articles (either systematic or comprehensive).
Dr. Cristian Scatena
Dr. Carmine De Angelis
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- breast cancer diagnosis
- cancer risk
- cell reprogramming
- biomarkers
- resistance
- precision therapy
